FDA

View All

MedTech News for Mammotome, Geneseeq, BaroPace
Smith+Nephew’s Hip Arthroplasty System; Mammotome Launched the HydroMARK Plus Breast Biopsy Site Marker; FDA Clearance for Pioneering MARS System; CE Marks for NGS-based Test Kits; BaroPace Updated on Non-Pharmacologic Hypertension and Heart Failure Treatment Trial; Quanta Completed Enrollment in Home Run Study

Smith+Nephew Launched Hip Arthroplasty System in India  On August 17, 2023, The London-based orthopedic device maker Smith+Nephew announced the launch of its OR3O dual mobility system for use in primary and revision hip arthroplasty in India. The dual mobility implants have a smaller-diameter femoral hea...

Find More

Pharma News for Gilead, Incannex, Avidity
Eylea HD Injection 8 Mg Approved By FDA; Veopoz Receives FDA Approval for CHAPLE Disease Treatment; FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials; FDA Approval to Incannex’s Sleep Apnoea Clinical Trial; FDA Orphan Drug Designation to Avidity’s AOC 1044; Orphan Drug Designation to CanariaBio’s MAb-AR20.5

Eylea HD Injection 8 Mg Approved By FDA for Treatment of Wet AMD, DME, and Diabetic Retinopathy The FDA has approved Regeneron Pharmaceuticals’ EYLEA HD (aflibercept) Injection of 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retin...

Find More

MedTech News for Viseon, ZimVie, Acorai
4WEB Medical’s Cervical Spine Plating Solution; Viseon Launched Visualization System for Minimally Invasive Spine Surgery; ZimVie’s New Mobi-C Implant; GE HealthCare’s Wireless Monitoring Solution; Acorai’s Non-Invasive Intracardiac Pressure Monitor; CytoSorbents’s STAR-T Pivotal Trial

4WEB Medical Launched its Cervical Spine Plating Solution  On August 15, 2023, 4WEB Medical, an orthopedic implant company focused on developing innovative implants that utilize its proprietary Truss Implant Technology™, launched the newest addition to the company's implant portfolio, the Cervical Spine Pla...

Find More

Pharma News for Janssen, Galera, Genprex
J&J’s 2-in-1 Tablet for Prostate Cancer; FDA Approves TALVEY for Heavily Pretreated Multiple Myeloma; PDS Biotech Updated on VERSATILE-003 Trial; FDA Issues CRL to NDA for Avasopasem in Radiotherapy-Induced Severe Oral Mucositis in HNC; FDA Orphan Drug Designation to Genprex’s REQORSA; FDA Orphan Drug Designation to Bloomsbury’s BGT-OTCD

FDA Clears J&J’s 2-in-1 Tablet for Prostate Cancer Johnson & Johnson's Janssen Pharmaceutical Companies stated that the US Food and Drug Administration (FDA) had approved AKEEGA (niraparib and abiraterone acetate), the first-and-only dual-action tablet combining a PARP inhibitor including abiraterone ace...

Find More

MedTech News for Quest, DuPont, BD
Quest Introduced Consumer-Initiated Blood Test for Alzheimer’s Disease Risk Assessment; DuPont Acquires Spectrum Plastics; BD Received 510(k) Clearance for Molecular Combination Test; Natera Updates on Phase III ALTAIR Trial of Signatera; Anteris’ DurAVR transcatheter heart valve Trial

Quest Introduced First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on Questhealth Website On July 31, 2023, Quest Diagnostics, a leader in diagnostic information services, announced the introduction of the AD-Detect™ Test for Alzheimer's Disease on questhealth.com – the first ...

Find More

Pharma News for Biogen, Astellas, Ascentage
FDA Approves ZURZUVAE for Postpartum Depression; Astellas Drug Acquired in $5.9B Deal Wins FDA Approval; FDA Clearance to Phase III Study of Lisaftoclax; FDA Issues CRL to BLA Resubmission for Remestemcel-L; Bavarian Nordic Updated on its Chikungunya Virus Vaccine; FDA Orphan Drug Designation to ABM-1310

FDA Approves ZURZUVAE, the First and Only Oral Treatment Approved for Women with Postpartum Depression Biogen Inc. and Sage Therapeutics, Inc. announced that the FDA has approved ZURZUVAE (zuranolone) 50 mg for individuals with postpartum depression (PPD). ZURZUVAE is the first and only 14-day oral, once-daily t...

Find More

MedTech News for icotec, Terumo, Genesis
Icotec’s VADER Pedicle System; Terumo BCT’ Reveos Automated Whole Blood Processing System; Genesis MedTech’s J-Valve Transfemoral System; STARmed Launched STARmed America in the USA

Genesis MedTech Announces FDA Breakthrough Device Designation for the J-Valve™ Transfemoral System Genesis MedTech, a leading medical device company, announced that the US Food and Drug Administration (FDA) has designated its J-ValveTM Transfemoral (TF) System as a Breakthrough Device. This innovative heart valv...

Find More

Pharma News for GSK, Biogen, Citius
FDA Expands GSK’s Jemperli Approval; Biogen to Acquire Reata Pharma; Enhertu Shows Survival Boost in HER2+ Solid Tumors; FDA Rejects Citius’ Revived IL-2 Therapy; FDA Fast Track designation to IVS-3001 for RCC; EU Orphan Drug Designation to Biohaven’s Taldefgrobep Alfa

FDA Expands GSK’s Jemperli Approval for Endometrial Cancer GSK plc announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with mismatch repair deficient...

Find More

MedTech News VARON, Biostrap, MediView XR, Magnus
VARON’s New VP Series Portable Oxygen Concentrator; Biostrap’s Wrist-Worn Digital Health Monitoring Device; MediView’s AR Navigation Platform; Beckman Coulter’s DxC 500 AU Chemistry Analyzer; Magnus Updated on Study Using SAINT Neuromodulation System; Francis Medical’s VAPOR 2 Pivotal Study

VARON Launched the Game-changer in the Field--New VP Series Portable Oxygen Concentrator On July 19, 2023, VARON, a leading oxygen concentrator manufacturer, announced the launch of a game-changer portable oxygen concentrator VP-2.  A new member of the VP series, VP-2 is incorporated with innovative tech...

Find More

Pharma News for Eli Lilly, Alnylam, Elevar
Lilly to Acquire Versanis; FDA Approves Beyfortus for RSV in Infants; Alnylam Presented Updates on Interim Phase 1 Results for ALN-APP; FDA Accepts NDA for Rivoceranib Plus Camrelizumab; FDA Fast Track Designation to Karyopharm’s Selinexor; Adcentrx’s IND Application for ADRX-0706

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases Eli Lilly & Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical firm focused on the discovery of novel medications for the treatment of cardiometab...

Find More